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Abstract 
 
Stevens–Johnson syndrome (SJS)/ Toxic Epidermal Necrolysis (TEN) are acute, self-limited, potentially life-threatening 
mucocutaneous disease. Oral mucosal involvement manifest as extensive erosions and haemorrhagic crusting, which can 
interfere oral functions causing odynophagia, inability to tolerate solid foods, and increased aspiration risk. A 40-year-old 
female patient was referred from Dermatology and Venereology department with diagnosis SJS/TEN overlap. The 
patient complained mouth opening difficulty due to mouth and lip sores. Drug history revealed positive intake of 
carbamazepine. Extraoral examination revealed multiple diffuse discrete facial lesions, conjunctival hyperemia, erosions 
and hemorrhagic crusting lips. Intraoral examination revealed white yellowish plaque, and erosions on buccal mucosa, 
palate, floor of the mouth, dorsal, ventral, and lateral tongue. Laboratory investigation revealed decrease of haemoglobin, 
hematocrite, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), thrombocyte, eosinophil, band 
of eosinophil, lymphocyte, natrium, potassium, and calcium. Oral lesions associated with SJS/TEN overlap diagnosis 
was made. Chlorhexidine gluconate 0,1%, nystatin oral suspension, vitamin B12, folic acid, and corticosteroid unguent 
compounding were given, which showed improvement of oral lesions in 3 weeks. SJS/TEN are the same disease 
spectrum of delayed hypersensitivity reaction leading to keratinocyte apoptosis through cytotoxic T-cell mediated Fas-
Fas ligand, perforin/ granzyme B, and granulysin, which distinguished primarily by severity and percentage of total body 
surface area involved.Currently, an optimal treatment standard for SJS/TEN patients remains unavailable. Oral lesions 
management play significant role in enhancing patients’ quality of life and achieving better prognosis in SJS/TEN 
overlap patients through multidisciplinary approach. 
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Abstrak 
 
Stevens–Johnson syndrome (SJS)/ Toxic Epidermal Necrolysis (TEN) merupakan penyakit mukokutan akut, sembuh 
sendiri, serta berpotensi membahayakan nyawa. Keterlibatan manifestasi oral berupa erosi ekstensif dan krusta hemoragi 
yang dapat mengganggu fungsi oral sehingga terjadi odinofagia, sulit mengunyah makanan padat, serta peningkatan 
risiko aspirasi. Seorang perempuan, 40 tahun dirujuk dari Departemen Ilmu Kulit dan Kelamin dengan diagnosis 
SJS/TEN overlap. Keluhan pasien meliputi kesulitan membuka mulut akibat sariawan pada bibir dan mulut. Riwayat 
obat menunjukkan konsumsi karbamazepin. Pemeriksaan ekstraoral ditemukan lesi multipel discrete difus, konjungtiva 
hiperemia, erosi dan krusta hemoragi pada bibir. Pemeriksaan intraoral ditemukan erosi pada mukosa oral. Pemeriksaan 
laboratorium ditemukan penurunan kadar haemoglobin, hematokrit, MCV, MCH, trombosit, eosinofil, eosinofil batang, 
limfosit, natrium, kalium, serta kalsium. Diagnosis ditegakkan sebagai lesi oral terkait SJS/ TEN overlap. Lesi oral 
mengalami penyembuhan setelah diberikan terapi klorheksidin glukonat 0,1%, suspensi oral nistatin, vitamin B12, asam 
folat, serta kortikosteroid topikal selama 3 minggu perawatan. SJS/ TEN merupakan spektrum penyakit yang serupa 
akibat reaksi hipersensitivitas tipe IV sehingga menyebabkan apoptosis keratinosit melalui sel T sitotoksik yang 
Management of Oral Lesions Associated with Carbamazepine-related Stevens-Johnson Syndrome/Toxic Epidermal         155 
Necrolysis Overlap Patient  
 
diperantarai ligan Fas-Fas, perforin/ granzyme B, serta granulysin, yang dibedakan terutama berdasarkan tingkat 
keparahan dan keterlibatan persentase total epidermolisis permukaan kulit tubuh. Sejauh ini belum terdapat 
penatalaksanan standar optimal untuk pasien SJS/ TEN. Penatalaksanaan lesi oral berperan penting dalam meningkatkan 
kualitas hidup pasien dan dalam upaya memperoleh prognosis lebih baik pada pasien SJS/ TEN melalui multidisiplin 
ilmu. 
 
Kata kunci: Lesi oral, Stevens-Johnson syndrome, toxic epidermal necrolysis 
 
 
 
INTRODUCTION 
 
An adverse drug reactions (ADR) is defined by the 
World Health Organization (WHO) as a response to 
a medicine which is noxious and unintended, and 
which occurs at doses normally used in mans, while 
drug allergy defined as an immunologically IgE or 
non-IgE mediated drug hypersensitivity reaction.
1 
ADR is a global phenomenon which affects all ages, 
with implicated risk factors including drug related 
factors that affect its immunogenicity include its abi-
lity to act as a hapten, a prohapten or to bind cova-
lently to immune receptors (P-i concept).
2
 The host 
related factors including increasing age and drugs in-
take, female appear more likely to develop drug al-
lergies than males, concomitant disease states such 
as immunosuppressed patients and autoimmune dis-
orders may predispose to the development of allergic 
drug reactions by altering metabolic pathways and 
inducing variations in the immunologic responses to 
drugs.The host genetic factor related with human 
leukocyte antigen (HLA) genotypes. It has been sug-
gested that major histocompatibility complex (MH 
C) presentation of drug derived antigen plays a key 
role in the development of drug hypersensiti-vity.
1
 
Drug eruptions or ADR range from transient ery-
thema to life-threatening severe cutaneous adverse 
reactions (SCAR) include drug-induced hypersen-
sitivity syndrome (DiHS), acute generalized exan-
thematous pustulosis (AGEP), drug reaction with eo-
sinophilia and systemic symptoms complex (DRE 
SS), Stevens–Johnson syndrome (SJS), and toxic 
epidermal necrolysis (TEN).
1,2 
SJS/ TEN represent 
different degrees of the same type of SCAR with 
high morbidity and mortality rates.
3 
The incidence of 
SJS specific ranges from 1.2 to 6 per million/ year, 
with fatality in 5% of cases, while TEN affects 0.4 to 
1.2 per million/ year with mortality of 30% of 
patients.
4 
The incidence of SJS/TEN in South East 
Asia is largely undetermined.
5
 
SJS/TEN are acute, self-limited, rapid onset, rare 
but severe, potentially life threatening mucocu-
taneous disease clinically characterized by wide-
spread epidermal necrosis with involvement of at 
least 2 mucous membranes, which predominantly 
triggered by ADR, rarely infections and malignan-
cies.
4,6
 There are over 100 medications of various 
classes associated with the occurrence of SJS/ TEN.
4
 
The high risk implicated drugs include antigout (al-
lopurinol), antiepileptic (carbamazepine/ CBZ, phe-
nytoin, phenobarbital, lamotrigine),  antibiotic (cot-
rimoxazole and other sulphonamides, floroquino-
lone), anti-inflamatory (sulfasalazine), anti-HIV (ne-
virapine), oxicamderivative nonsteroidal antiinfla-
matory drugs (meloxicam), and analgesic (parace-
tamol).
3-5,7 
SJS/ TEN mostly results from a cumu-
lative effect of aligned risks related to drug structure 
and to the patient’s genetic predisposition (HLA 
alleles, drug metabolism characteristics, and T cell 
clonotypes),
3
 as well as ethnic specific.
5
 SJS/ TEN 
were historically considered part of a spectrum of 
erythema multiforme major, as they all present with 
mucosal lesions clinically similar, but these diseases 
are now considered apart.
4,8
 SJS is defined by 10% 
or less of total body surface area involvement while 
TEN is defined by 30% or greater involvement. Bo-
dy surface involvement between 10–30% is known 
as SJS/ TEN overlap.
6
 
Oral mucosal involvement manifests as extensive 
erosions and haemorrhagic crusting, which can inter-
fere oral functions causing odynophagia, inability to 
tolerate solid foods, and increased aspiration risk. 
The treatment of SJS/ TEN is multidisciplinary ap-
proach and there are still no internationally accepted 
management guidelines or an optimal treatment 
standard for SJS/ TEN.
3 
In this case report, we pre-
sent a case of oral lesions management in SJS/ TEN 
overlap patient. 
 
CASE REPORT 
 
A 40-year-old female patient was referred from 
Dermatology and Venereology department with di-
agnosis SJS/ TEN overlap. The patient reported that 
she had chronic jaw pain for approximately 3 years 
since her last dental extraction. Three months before 
admitted to hospital, she went to her regular dentist 
who referred her to a neurology specialist. Two we-
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eks before admitted to hospital, the neurology spe-
cialist prescribed her CBZ. She complained red eye, 
mouth opening difficulty due to mouth and lip sores, 
and widespread rashes on her neck, one day before 
admitted to hospital with preceding fever. She stated 
that she had no history of allergy. 
Extraoral examination revealed multiple diffuse 
discrete facial lesions, conjunctival hyperemia, eyes 
and ears secrets, erosions and hemorrhagic crusting 
lips, and her whole body except scalp, palms, and 
sole of feet was covered with multiple rashes, ve-
sicle, and epidermolysis bullae. Intraoral examina-
tion revealed white yellowish plaque, and erosions 
on buccal mucosa, palate, floor of the mouth, dorsal, 
ventral, and lateral tongue (Fig. 1). 
 
  
 
  
 
Fig.1A-C. Clinical manifestations of SJS/ TEN overlap 
showed widespread rashes (A), ear secrets (B), multiple 
erosions and hemorrhagic crust on lips (C), and oral 
candidiasis on dorsal tongue (D). 
 
Laboratory investigation revealed decrease of hae-
moglobin, hematocrite, MCV, MCH, thrombocyte, 
eosinophil, band of eosinophil, lymphocyte, natrium, 
potassium, and calcium. Oral lesions associated with 
SJS/ TEN overlap diagnosis was made.  
 
CASE MANAGEMENT 
 
The patient was hospitalized for 2 weeks and wi-
thin this periode, regimen from dermatology and ve-
nereology department include dexamethasone 30 mg 
via IV, omeprazole 40 mg via IV,  ibuprofen 500 mg 
three times daily, cendo lyteers 1 ml every one hour. 
We treated the oral lesions with topical cortico-
steroid (TC) unguent compounding of cortico-
steroids (dexamethasone) 0.05 mg + antihistamine 
(pheniramine maleate: avil) 0.5 mg + emollient base 
(lanolin) 2.5 g + petroleum jelly based (vaseline) 25 
g] three times daily, chlorhexidine gluconate 0,1% 
three times daily, nystatin oral suspension 2 ml four 
times daily, vitamin B12 50 mcg three times daily, 
and folic acid 1 mg once daily. All oral lesions gra-
dually resolved in 3 weeks (Fig. 2,3, and 4). 
 
   
 
  
 
Fig.2A-D. Slight improvement of lesions in first visit or a 
1-week-follow-up. 
 
  
 
  
 
Fig.3A-D. Improvement of lesions in second visit or 2-
week-follow-up. 
 
  
 
  
 
Fig.4A-D. Lesions healed in third visit or 3-week-follow-
up.
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DISCUSSION 
 
There was history of CBZ intake, two weeks be-
fore patient admitted to hospital. SJS/ TEN is an im-
mune disorder mostly caused by drugs, rarely in-
fections (especially Mycoplasma pneumonia), hu-
man immunodeficiency virus (HIV), vaccinations, 
radiotherapy and  concomitant diseases such as graft 
versus host disease (GVHD), lymphomas, leukae-
mias and systemic lupus erythematosus.
2
 CBZ is an 
antiepileptic drugs (AED) that is effective in some 
people with chronic neuropathic pain,
9
 but the use of 
aromatic AED include CBZ, phenytoin, oxcarba-
zepine, phenobarbital, primidone, zonisamide, and 
lamotrigine is more frequently associated with drug-
induced hypersensitivity reactions such as SJS/ 
TEN.
4,5,7,10
 The highest risk of developing SJS/ TEN 
occurs in the first 2 months of treatment with the 
usage of drugs on a continuous basis.
4 
The risk/ pre-
disposing factors of drug-induced SJS/ TEN include 
specific HLA allele, pharmacogenetic variations in 
drug biotransformation or clearance, sex, hormones, 
drug doses or titration schedule (low dose <10 
mg/day and gradual titration may allow desensitiza-
tion and pharmacodynamics tolerance), and co-
medication. The chemical structures of aromatic ring 
in AED might induce allergy via T-cell-mediated 
(delayed type IV) hypersensitivity reactions.
10
 
CBZ is one of example of the p-i concept (pharma-
cological interaction of drugs with immune recep-
tors). The low molecular weight drug act as foreign 
antigen which binding directly and reversibly to T 
cell receptors (TCRs), then involved in presenting to 
HLA molecules of antigen-presenting cells (APCs) 
and provoke T cell activation. The HLA–drug–
TCRs may initiate a series of immune reactions, 
which result in activation of CD8+ cytotoxic T cell–
mediated and natural killer (NK) cell–mediated 
cytotoxicity. While CD8+ cytotoxic T cells and NK 
cells are activated, they subsequently carry out the 
cellular-mediated immune reactions directed at ke-
ratinocytes in an HLA class I–restricted manner. 
Upon activation of these responses, various cyto-
toxic signaling molecules or cell death mediators, in-
cluding granulysin, perforin/granzyme B, and Fas/ 
Fas ligand, and annexin A1 are relayed to the skin 
lesions to induce keratinocyte apoptosis. Several cy-
tokines/chemokines involved in the pathogenesis of 
SJS/TEN include interleukin (IL)-2, IL-5, IL-6, IL-
10, IL-12, IL-13, IL-15, IL-18, chemokine (C–C 
motif) receptor (CCR) 3, chemokine (C-X-C motif) 
receptor (CXCR) 3, CXCR4, and CCR10, which 
can induce cell apoptosis, activation, and differen-
tiation, and an inflammatory response.
3,11
 
The patient’s complaint began with a preceding fe-
ver following with red eye, mouth opening difficulty 
due to mouth and lip sores, and widespread rashes 
on her neck, one day before admitted to hospital. 
The onset of signs and symptomsof SJS/ TEN oc-
curs 4 to 28 days after drug exposure, which can 
start, although not always, with typical or classical 
prodromal phase that may precede the rash by 1-2 
days and lasting up to 1 week, consists of unspecific 
initial flu-like symptoms (malaise, fever, anorexia), 
sore throat, coughing, eye burning, myalgia and ar-
thralgia. After this period, The initial skin rash, 
which appear suddenly and symmetrically, may be 
erythematous maculopapular with irregular shape or 
similar to a morbilliform rash, urticarial, purpuric or 
targetoid and is specifically tender. They usually be-
gins on the presternal region of the trunk and rapidly 
spread over 3-12 days to involve the face, neck and 
extremities, also the palms and soles. Macular le-
sions become purplish or dusky dark red purpuric, 
with tendency to rapidly develop flaccid blisters that 
coalesced as atypical target lesions and break, re-
sulting epidermal detachment in erythematous, oozy, 
raw lesions, and extensive sloughing of necrotic 
skin, which can easily become infected. The Nikol-
sky’s sign is positive in perilesional skin if mecha-
nical pressure induces epidermal detachment, al-
though it is not specific for SJS/ TEN, as it can also 
be positive in autoimmune bullous skin diseases. 
Mucosal involvement may precede or follow the 
skin manifestations and occurs in two or more dis-
tinct mucosal surfaces such as ocular, ear, nose, and 
throat (ENT), oral, and genital lesions with clinical 
morphologies include erythema, enanthem, edema, 
and vesiculobullous that cause painful hemorrhagic 
erosions, coated by greyish-white  pseudomem-
branes formations.
3,4,8,11-3 
Involvement of oral mu-
cosa is seen in most of the cases with burning sen-
sation, edema and erythema following with wide-
spread and painful mucosal erosions or ulcerations, 
mostly on buccal, palatal mucosa, tongue, gingiva 
and lips.
12,14
The extensive erosions and haemor-
rhagic crusting can interfere oral functions causing 
odynophagia, inability to tolerate solid foods, and in-
creased aspiration risk.
12,15
 All the clinical manifes-
tations of SJS/ TEN overlap in our patient is con-
cordant with the literature explained above.
 
There is still no universal diagnostic criteria for 
SJS/ TEN.
16
The diagnosis of SJS/ TEN is based on 
anamnesis, clinical manifestations, and histopatho-
logical findings.
3,4,11
All medications, regardless of 
the route of administration, must be considered, es-
pecially new drugs taken in the 8 weeks prior to the 
skin reaction. Assessment of the lag period (the time 
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between initiation of the drug and the onset of the 
cutaneous reaction) is 4–28 days for SJS/TEN which 
crucial in view of the different lag times for different 
cutaneous drug reactions. A comprehensive physical 
examination consists of prodromal phase, followed 
by erythema, maculopapular rash, targetoid lesions, 
bullae, desquamation, mucosal inflammation, and/ 
or positive Nikolsky sign and with other systemic in-
volvement must be assessed to get accurate diag-
nosis of SJS/TEN.To distinguish SJS, SJS-TEN 
overlap and TEN, Bastuji-Garin et al. proposed pa-
tient classification  based on the body surface area 
percentage of skin detachment (% BSA). SJS is 
characterized by <10% BSA affected, SJS-TEN 
Overlap is between 10 and 30% BSA, and TEN is 
>30% BSA.
3,4,8,11,16
Based on % BSA finding and 
having 2 or more mucosal membrane involvement, 
our patient categorized as SJS/TEN overlap. La-
boratory investigation in our patient revealed de-
crease of haemoglobin, hematocrite, MCV, MCH, 
thrombocyte, eosinophil, band of eosinophil, lym-
phocyte, natrium, potassium, and calcium. Various 
laboratory abnormalities were noted in several SJS/ 
TEN patients such as increased markers of acute 
inflammation. There are still no specific laboratory 
investigitations.
3,4,11 
Furthermore, there is still incon-
sistency in the indication for biopsy as an inclusion 
criterion,
16
with characteristic histopathology reveals 
keratinocyte necrosis and varying degrees of dermal-
epidermal separation.
3,16
 Based on anamnesis, clinic-
al examinations, and without biopsy examination, 
we diagnosed the case of our patient as oral lesions 
associated with SJS/TEN overlap. 
There are still no internationally accepted mana-
gement guidelines of SJS/ TEN. Management of 
SJS/ TEN involves the early identification and re-
moval of the triggers, particularly drugs known to be 
high-risk, followed by multidisciplinary approach to 
alleviate symptoms and prevent further complica-
tions of the disease. There are several pharmaco-
logical therapies available, such as corticosteroids, 
intravenous immunoglobulins (IVIG), and cyclos-
porine. However, a universally accepted drug treat-
ment regimen has not been established, and much 
controversy exists as to the role of each of these 
drugs individually or in combination.
3,4,13 
The role of 
corticosteroids in treatment of SJS/ TEN is contro-
versial because it may promote infectious compli-
cations and lead to a poorer prognosis. However, 
corticosteroid treatment did not increased mortality 
in SJS/ TEN patients.The patient was hospitalized 
for 2 weeks and dexamethasone IV, omeprazole  IV, 
ibuprofen, and cendo lyteers were given by der-
matology and venereology specialist. Systemic cor-
ticosteroids with a high dose are considered to be 
able to suppress the intensity of immune reaction, 
control the extension of the necrolytic process, de-
crease the injury area, reduce fever and discomfort, 
and prevent damage to internal organs in SJS/ TEN 
patients at the early stage. Furthermore, a review of 
the highest quality evidence concluded that steroid 
use in patients with SJS, SJS/TEN overlap, and TEN 
does not reveal an increase in mortality.
13
 
We treated the oral lesions with TC, chlorhexidine 
mouthwash, vitamin B12, and folic acid, which re-
solved in 3 weeks. Mucosal hygienic maintenance 
are of prime importance to increase patient's com-
fort, to facilitate epithelialization and to prevent 
complications such as infections.
17 
Specific oral care 
strategies can be used to minimize trauma during 
oral functions such as using smaller utensils and 
syringes.
15
 Corticosteroids play a central role in the 
treatment of vesiculo erosive oral lesions of auto-
immune and or immunologically mediated diseases, 
but the evidence for the efficacy of TC in oral me-
dicine is limited, and many of the protocols followed 
are drawn from experience gained in a derma-
tological use.
17
Those major challenges becomes 
more problematic as there are very few commercial 
products are currently available for the topical treat-
ment of the oral mucosal lesions. Therefore, com-
poundding is often required.
18 
Other drugs of choice 
to treat erosions include chlorhexidine, octenisept or 
polyhexanide solutions and impregnated nonad-
hesive mesh gauze.
8 
Vitamin B12  and folid acid 
were given in order to induce erythropoiesis.Others 
pharmacological therapy can be delivered, if needed, 
such as topical lignocaine gel, antifungal agents (ny-
statin), others antiseptic mouthwash (e.g., bicar-
bonated soda, half-strength hydrogen peroxide), and 
topical cream to the lips (e.g., vasoline, lano-
lin).
15,19,20 
Oral lesions management play significant role in 
enhancing patients’ quality of life and achieving 
better prognosis in SJS/TEN overlap patients 
through multidisciplinary approach. Comprehensive 
management of oral lesion in SJS/ TEN overlap in-
cluding topical corticosteroid, oral hygiene instruc-
tion, and patients’ adherence. 
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